Back to Search Start Over

Reliability and agreement of radiological and pathological tumor size in patients with multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: results from a population-based cohort

Authors :
Geert Kazemier
Sjoerd Nell
Menno R. Vriens
Helena M. Verkooijen
Cornelis H. C. Dejong
Frederik J. H. Hoogwater
Inne H.M. Borel Rinkes
Harry van Goor
Lodewijk A.A. Brosens
Casper H.J. van Eijck
Dirk-Jan van Beek
Bert A. Bonsing
Gerlof D. Valk
Elisabeth J. M. Nieveen van Dijkum
Frank J. Wessels
CCA - Cancer Treatment and quality of life
Surgery
Amsterdam Gastroenterology Endocrinology Metabolism
Pathology
MUMC+: MA Heelkunde (9)
RS: NUTRIM - R2 - Liver and digestive health
Source :
Neuroendocrinology, 111(8), 705-717. KARGER, Neuroendocrinology, 111, 8, pp. 705-717, van Beek, D-J, Verkooijen, H M, Nell, S, Bonsing, B A, van Eijck, C H, van Goor, H, Hoogwater, F J H, Nieveen van Dijkum, E J M, Kazemier, G, Dejong, C H C, Brosens, L A A, Wessels, F J, Borel Rinkes, I H M, Valk, G D & Vriens, M R 2021, ' Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort ', Neuroendocrinology, vol. 111, no. 8, pp. 705-717 . https://doi.org/10.1159/000510514, Neuroendocrinology, 111(8), 705-717. S. Karger AG, Neuroendocrinology, 111(8), 705-717. Karger, Neuroendocrinology, 111, 705-717, Neuroendocrinology
Publication Year :
2021

Abstract

Background: Pancreatic neuroendocrine tumors (pNETs) have a high prevalence in patients with multiple endocrine neoplasia type 1 (MEN1) and are the leading cause of death. Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision-making. We assessed reliability and agreement of radiological and pathological tumor size in a population-based cohort of patients with MEN1-related pNETs. Methods: Patients were selected from the Dutch MEN1 database if they had undergone a resection for a pNET between 2003 and 2018. Radiological (MRI, CT, and endoscopic ultrasonography [EUS]) and pathological tumor size were collected from patient records. Measures of agreement (Bland-Altman plots with limits of agreement [LoA] and absolute agreement) and reliability (intraclass correlation coefficients [ICC] and unweighted kappa) were calculated for continuous and categorized (< or ≥2 cm) pNET size. Results: In 73 included patients, the median radiological and pathological tumor sizes measured were 22 (3–160) and 21 (4–200) mm, respectively. Mean bias between radiological and pathological tumor size was −0.2 mm and LoA ranged from −12.9 to 12.6 mm. For the subgroups of MRI, CT, and EUS, LoA of radiological and pathological tumor size ranged from −9.6 to 10.9, −15.9 to 15.8, and −13.9 to 11.0, respectively. ICCs for the overall cohort, MRI, CT, and EUS were 0.80, 0.86, 0.75, and 0.76, respectively. Based on the 2 cm criterion, agreement was 81.5%; hence, 12 patients (18.5%) were classified differently between imaging and pathology. Absolute agreement and kappa values of MRI, CT, and EUS were 88.6, 85.7, and 75.0%, and 0.77, 0.71, and 0.50, respectively. Conclusion: Within a population-based cohort, MEN1-related pNET size was not systematically over- or underestimated on preoperative imaging. Based on agreement and reliability measures, MRI is the preferred imaging modality.

Details

Language :
English
ISSN :
00283835
Database :
OpenAIRE
Journal :
Neuroendocrinology, 111(8), 705-717. KARGER, Neuroendocrinology, 111, 8, pp. 705-717, van Beek, D-J, Verkooijen, H M, Nell, S, Bonsing, B A, van Eijck, C H, van Goor, H, Hoogwater, F J H, Nieveen van Dijkum, E J M, Kazemier, G, Dejong, C H C, Brosens, L A A, Wessels, F J, Borel Rinkes, I H M, Valk, G D & Vriens, M R 2021, ' Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort ', Neuroendocrinology, vol. 111, no. 8, pp. 705-717 . https://doi.org/10.1159/000510514, Neuroendocrinology, 111(8), 705-717. S. Karger AG, Neuroendocrinology, 111(8), 705-717. Karger, Neuroendocrinology, 111, 705-717, Neuroendocrinology
Accession number :
edsair.doi.dedup.....9414febfb0aeb342e90604a184fef078